Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi's sarcoma in Brazil

HIV Clinical Trials

Volumn 7, Issue 4, 2006, Pages 194-202

  Vanni, Tazio ^a   Lopes Fonseca, Benedito Antonio ^a   Polanczyk, Carisi Anne ^b,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Chemotherapy; Cost effectiveness; Kaposi's sarcoma

Indexed keywords

BLEOMYCIN; COLONY STIMULATING FACTOR; DOXORUBICIN; VINCRISTINE;

AIDS RELATED COMPLEX; ALOPECIA; ARTICLE; BRAZIL; CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DATA ANALYSIS; DEVELOPING COUNTRY; DOSE RESPONSE; DRUG CHOICE; DRUG COST; DRUG FORMULATION; DRUG RESPONSE; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; KAPOSI SARCOMA; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; NEUROPATHY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ADMINISTRATION, ORAL; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLEOMYCIN; BRAZIL; COST-BENEFIT ANALYSIS; DAUNORUBICIN; DECISION SUPPORT TECHNIQUES; DOXORUBICIN; HUMANS; LIPOSOMES; POLYETHYLENE GLYCOLS; SARCOMA, KAPOSI; SENSITIVITY AND SPECIFICITY; VINCRISTINE;

EID: 33750850799     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0704-194     Document Type: Article

References (33)

1. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823-1830.
2. Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies: an international perspective. Hematol Oncol Clin N Am. 2003;17:673-696.
3. Grulich AE, Li Y, McDonald AM, et a]. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination antiretroviral therapy. AIDS. 2001;15:629-633.
4. Mocroft A, Kirk O, Clumeck N, et a]. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: The EuroSIDA Study. Cancer. 2004; 100(12):2644-2654.
5. Sitas F, Newton R. Kaposi's sarcoma in South Africa. J Natl Cancer Inst. 2000;28:1-4.
6. Wabinga HR, Parkin DM, Wabwire-Mangen F, et al. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer. 2000;82:1585-1592.
7. Echimane AK, Ahnoux AA Adoubi I, et al. Cancer incidence in Abidjan, Ivory Coast: first results from the cancer registry, 1995-1997. Cancer. 2000;89:653-663.
8. Bassett MT, Chokunonga E, Mauchaza B, et al. Cancer in the African population of Harare, Zimbabwe, 1990-1992. Int J Cancer. 1995;63:9-36.
9. Parkin DM, Wabinga H, Nambooze S, et al. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS. 1999;13:2563-2570.
10. Teixeira PR, Vitoria MA, Barcarolo J, et al. Antiretroviral treatment in resource-poor settings: the Brazilian exprience. AIDS. 2004;18(suppl 3):S5-7.
11. Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur J Cancer. 2001;37: 1288-1295.
12. Von Roenn JH. Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin N Am. 2003; 17:747-762.
13. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol. 2004;22:399-402.
14. Olweny CL, Borok M, Gudza I, et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer. 2005;113:632-639.
15. Bennett CL, Golub RM, Stinson TJ, et al. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr. 1998;18(5):460-465.
16. Hjortsberg C, Person U, Lidbrink E, et al. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. Acta Oncol. 1999;38(8):1063-1067.
17. Welte R, Feenstra T, Jager H. A decision chart for assessing and improving the transferability of economic evaluations results between countries. Pharmacoeconomics. 2004;22(13):857-876.
18. Gill PS, Wemz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS related Kaposi's sarcoma. J Clin Oncol. 1996;14:2353-2364.
19. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16:2445-2451.
20. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst. 1993;85: 1460-1474.
21. Bennett CL, Armitage JL, Buchner D, et al. Economic analysis in phase III clinical cancer trials. Cancer Invest. 1994;12:336-342.
22. Stewart JSW, Jabonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 1998;16:683-691.
23. Krown SE, Metroka C, Wemz JC. Kaposi's sarcoma and the acquired immunedeficiency syndrome: a proposal for a uniform evaluation, response and staging criteria. J Clin Oncol. 1989;7:1201-1207.
24. Krown SE, Testa MA, Huang J, at al. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trial Group staging classification. J Clin Oncol. 1997;15:3085-3092.
25. Brazilian Ministry of Health - Health Prices Data Bank 2004 (Banco de Pregos ern Saúde - Ministério da Saúde 2004). Available at: http://owssrv1.saude.gov.br/bprefd/owa/consulta.inicio. Accessed September 10, 2005.
26. Rosenthal E, Poizot-Martin I, Saint-Marc T, et al. Phase IV study of liposomal daunorubicin DaunoXome) in AIDS-related Kaposi sarcoma. Am J Clin Oncol. 2002;25:57-59.
27. Martín-Carbonero L, Barrios A, Saballs P, et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS. 2004;18:1737-1740.
28. Tulpule A, Yung RC, Wemz J, et al. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. J Clin Oncol. 1998; 16:3369-3374.
29. Bower M, Fox P, Fife K, et al. Highly active antiretroviral therapy prolongs time to treatment failure in Kaposi's sarcoma. AIDS. 1999; 13:2105-2111.
30. Leitch H, Trudeau M, Routy JP. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy. HIV Clin Thals. 2003;4:107-114.
31. Lichterfeld M, Qurishi N, Hoffmann C, at al. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection. 2005;33:140-147.
32. Lynen L, Zolfo M, Huyst V, et al. Management of Kaposi's sarcoma in resource-limited setting in the era of HAART. AIDS Reviews. 2005;7:13-21.
33. Dedicoat M, Vaithilingum M, Newton R. Treatment of Kaposi's sarcoma in HIV-1 infected individuals with emphasis on resource poor settings (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Oxford: Update Software.